On March 8, 2022 Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, reported that it will present posters for three of the company’s preclinical pipeline programs at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, being held in-person and virtually at the Ernest N. Morial Convention Center in New Orleans, LA from April 8-13, 2022 (Press release, Bolt Biotherapeutics, MAR 8, 2022, View Source [SID1234618689]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present three poster presentations at the AACR (Free AACR Whitepaper) Annual Meeting that highlight the significant progress made by our research team and the depth of our expertise in myeloid biology. We are continuing to expand our Boltbody ISAC platform with advanced CEA- and PD-L1-targeting ISACs, both of which have the potential to provide cancer patients with new options where few treatments are currently available. We are expanding our pipeline beyond ISACs through the development of our novel myeloid modulating antibody, BDC-3042, which repolarizes tumor-associated macrophages, or TAMs, into tumor destructive macrophages via agonism of Dectin-2," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.

Three of Bolt Biotherapeutics’ preclinical programs will be featured in poster presentations: (1) BDC-2034, a CEA-targeting immune-stimulating antibody conjugate (ISAC) expected to enter clinical development in the second half of 2022, (2) BDC-3042, a Dectin-2-targeting, myeloid-modulating antibody anticipated to enter clinical development in 2023, and (3) a PD-L1-targeting ISAC. These posters will highlight updates on preclinical research for each of the programs, demonstrating anti-tumor activity and supporting future clinical development for all three programs.

Poster presentation sessions will be conducted in-person and available electronically on April 12 and 13 and will be published in Proceedings of the AACR (Free AACR Whitepaper). Details for each presentation can be seen below and on the AACR (Free AACR Whitepaper) website.

Title: The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming
Presenter: William G. Mallet, Ph.D.
Session Date and Time: Tuesday Apr 12, 2022, 9:00 a.m. – 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Poster Board Number: 26
Abstract Number: 2911

Title: Dectin-2 agonist antibodies reprogram tumor-associated macrophages to drive anti-tumor immunity
Presenter: Shelley Ackerman, Ph.D.
Session Date and Time: Tuesday Apr 12, 2022, 9:00 a.m. – 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Poster Board Number: 26
Abstract Number: 2883

Title: PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models
Presenter: Justin Kenkel, Ph.D.
Session Date and Time: Wednesday Apr 13, 2022, 9:00 a.m. – 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 39
Poster Board Number: 11
Abstract Number: 4252

About the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) Platform
ISACs are a new category of immunotherapy that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems. Boltbody ISACs comprise three primary components: a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune stimulant to activate the patient’s innate immune system. By initially targeting a single marker on the surface of a patient’s tumor cells, an ISAC can create a new immune response by activating and recruiting myeloid cells. The activated myeloid cells start a feed-forward loop by releasing cytokines and chemokines, chemical signals that attract other immune cells and lower the activation threshold for an immune response. This reprograms the tumor microenvironment and invokes an adaptive immune response that targets the tumor, which can lead to the conversion of immunologically "cold" tumors to "hot" tumors with the goal of durable responses for patients with cancer.

On March 8, 2022 Akari Therapeutics, Plc (Nasdaq: AKTX) ("Akari" or the "Company"), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, reported that it has entered into definitive agreements with certain institutional investors, accredited investors, and Dr. Ray Prudo, Akari’s Chairman, to receive gross proceeds of approximately $9.0 million (Press release, Akari Therapeutics, MAR 8, 2022, View Source [SID1234609638]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the offering, the Company will issue approximately 7,500,000 registered American Depository Shares (ADSs) of Akari at a purchase price of $1.20 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive a registered warrant to purchase one-half of one ADS. The warrants will have an exercise price of $1.40 per ADS, will be exercisable upon their issuance and will expire five years from the issuance date. The closing of the offering is expected to take place on or about March 10, 2022, subject to the satisfaction of customary closing conditions.

Paulson Investment Company, LLC, is acting as the exclusive placement agent in connection with this offering.

The securities described above are being offered by Akari pursuant to an effective shelf registration statement on Form F-3 (File No. 333-251673) previously filed with the Securities and Exchange Commission (the "SEC") on December 23, 2020 and declared effective by the SEC on December 31, 2020. The offering of the securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

The Company will file a prospectus supplement and the accompanying base prospectus with the SEC relating to the securities being offered. When available, electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained at the SEC’s website at View Source, or by contacting Donald A. Wojnowski Jr. of Paulson Investment Company, LLC, at (855) 653-3444 or at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On March 8, 2022 Phost’in Therapeutics (Montpellier, France), a biotech company focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, reported TechShare 2022, the pan-European pre-IPO educational program of Euronext. For the 7th year, Euronext is renewing its annual support program for growing European Tech companies (digital, cleantech and healthcare) aiming to go public (Press release, Phost’in, MAR 8, 2022, View Source [SID1234609655]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This year, more than 120 companies will join the program, including 40 from France, but also 9 other European countries: Germany, Belgium, Spain, France, Ireland, Italy, Norway, Netherlands, Portugal and Switzerland.

Phost’in Therapeutics was selected after a selection process and a presentation to the final jury composed of representatives of TechShare’s Selection partners* in France.

As a participant of the TechShare program, Phost’in Therapeutics will benefit from support of market experts and already quoted peers to understand the motivations and mechanisms of an IPO. Through a structured training around an academic campus, workshops and individual sessions, participants will be trained in the steps and challenges of an IPO, the building of an equity story and of a company valuation, understanding investors’ expectations, good practices in financial communication, corporate governance and post-quotation obligations. The cornerstone of the program is to promote networking and experience sharing between participating entrepreneurs, financial market experts and managers of quoted companies.

With more than 750 Tech companies quoted on our markets, Euronext is the leading quotation place for Tech companies in Europe. In 2021, Euronext recorded an ever set high record of 212 listings, with more than 50% of companies from the Tech sector. Euronext Paris hosted a record of 64 quotations in 2021 for nearly 4 billion euros raised, including 54 SMEs-ETIs. Since its launch in 2015, TechShare has welcomed nearly 170 Alumni in France. 10 of these French companies completed an IPO, 6 of them in less than a year, illustrating the market dynamics and growing maturity of the TechShare community.

Karine Chorro, CEO of Phost’in Therapeutics, said: "We are proud of this selection, and thrilled to take advantage of this opportunity to discuss with quoted companies and the best experts in the ecosystem. This experience should help us to prepare and select the best solutions to ensure our growth, and consolidate our position as a European leader in the Glyco-Immuno-Oncology field, as our first program, the First-In-Class Phox430 is enterin clinical steps. »

The TechShare 2022 program is also supported by the following institutional partners: AFPC (Association Française des Pôles de Compétitivité, i.e. French association of competitiveness clusters), Bpifrance, CroissancePlus, France Biotech, FranceDigitale, France Fintech, France Invest, GreenUnivers, La French Tech, Réseau PEXE, The Galion Project, WILLA.

On March 8, 2022 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that it will present an e-poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online (Press release, CRISPR Therapeutics, MAR 8, 2022, View Source [SID1234609672]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-β for cancer immunotherapy
Session Title: Preclinical Immunotherapy
Session Category: Immunology
Abstract Number: 5512, e-poster
Date and Time: Friday, April 8, 2022, 1:00 p.m. via the AACR (Free AACR Whitepaper) website, www.aacr.org

On March 8, 2022 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported that it will report financial results and provide business updates for the fourth quarter and year ended December 31, 2021, before the US markets open on Monday, March 14, 2022 (Press release, Adaptimmune, MAR 8, 2022, View Source [SID1234609688]). Following the announcement, the Company will host a live teleconference and webcast at 8:30 a.m. EDT (12:30 p.m. GMT) that same day (details below).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release and the live webcast of the conference call will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. A live webcast of the conference call and replay can be accessed at https://bit.ly/3utRMny.

To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (1343635).